Gregg Williams Buys 1,737,764 Shares of Vivani Medical (NASDAQ:VANI) Stock

Vivani Medical, Inc. (NASDAQ:VANI) Director Gregg Williams acquired 1,737,764 shares of the business’s stock in a transaction dated Saturday, November 15th. The stock was acquired at an average cost of $1.14 per share, with a total value of $1,981,050.96. Following the purchase, the director directly owned 23,088,579 shares in the company, valued at $26,320,980.06. This represents a 8.14% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Gregg Williams also recently made the following trade(s):

• On Monday, October 27th, Gregg Williams bought 3,703,703 shares of Vivani Medical stock. The shares were acquired at an average cost of $1.62 per share, for a total transaction of $5,999,998.86.
• On Wednesday, October 15th, Gregg Williams purchased 1,737,764 shares of Vivani Medical stock. The stock was acquired at an average cost of $1.14 per share, with a total value of $1,981,050.96.
• On Monday, September 15th, Gregg Williams purchased 2,068,453 shares of Vivani Medical stock. The shares were acquired at an average price of $1.16 per share, with a total value of $2,399,405.48.

Vivani Medical Trading Down 4.1%

Shares of NASDAQ:VANI opened at $1.41 on Wednesday. The stock has a market capitalization of $89.18 million, a P/E ratio of -3.13 and a beta of 3.15. The stock’s 50-day moving average price is $1.47 and its 200-day moving average price is $1.33. Vivani Medical, Inc. has a 12-month low of $0.91 and a 12-month high of $1.92.

Vivani Medical (NASDAQ:VANI) last released its earnings results on Thursday, November 13th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01. As a group, research analysts predict that Vivani Medical, Inc. will post -0.41 EPS for the current year.

Institutional Trading of Vivani Medical

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Susquehanna International Group LLP lifted its position in shares of Vivani Medical by 100.5% in the 3rd quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock worth $46,000 after purchasing an additional 16,200 shares during the period. Citadel Advisors LLC bought a new position in Vivani Medical in the third quarter worth about $26,000. Panagora Asset Management Inc. purchased a new stake in Vivani Medical in the second quarter worth about $25,000. Wealthedge Investment Advisors LLC boosted its position in Vivani Medical by 238.8% during the 1st quarter. Wealthedge Investment Advisors LLC now owns 125,033 shares of the company’s stock valued at $131,000 after acquiring an additional 88,132 shares in the last quarter. Finally, Connective Capital Management LLC grew its holdings in shares of Vivani Medical by 796.2% during the 1st quarter. Connective Capital Management LLC now owns 162,098 shares of the company’s stock worth $170,000 after acquiring an additional 144,010 shares during the period. Hedge funds and other institutional investors own 6.78% of the company’s stock.

Wall Street Analysts Forecast Growth

VANI has been the topic of several recent analyst reports. Zacks Research upgraded shares of Vivani Medical from a “strong sell” rating to a “hold” rating in a report on Wednesday, November 12th. HC Wainwright reissued a “buy” rating and set a $4.00 price target on shares of Vivani Medical in a research report on Tuesday, September 2nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vivani Medical in a research report on Tuesday, October 14th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $4.00.

Vivani Medical Company Profile

Vivani Medical, Inc, a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals.